Volume 3.43 | Nov 3

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Researchers devised an inducible T-cell safety switch that is based on the fusion of human caspase 9 to a modified human FK-binding protein, allowing conditional dimerization. They tested the activity of the safety switch by introducing the gene into donor T cells given to enhance immune reconstitution in recipients of haploidentical stem-cell transplants. [N Engl J Med] Abstract | Press Release

Long-Term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
Researchers’ objective was to describe outcomes of patients 60 years or older after receiving minimally toxic nonmyeloablative allogeneic hematopoietic cell transplantation. [JAMA] Abstract | Press Release

Indolent T-Cell Large Granular Lymphocyte Leukemia After Hematopoietic SCT: A Clinicopathologic and Molecular Analysis
Four women and three men after allogeneic (n=4) and autologous (n=3) hematopoietic stem cell transplantation (HSCT) were observed to have an increase in T-cell large granular lymphocytes of CD3+CD8+ phenotype for a median of 41 (15–118) months. [Bone Marrow Transplant] Abstract

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared to Children and Older Adults with Acute Myeloid Leukemia
Researchers compared outcomes among children (less than 15 years), adolescents and young adults (15-40 years) and older adults (greater than 40 years) receiving allogeneic hematopoietic cell transplant for acute myeloid leukemia. [Biol Blood Marrow Transplant] Abstract

Megakaryocytopoiesis and Thrombopoiesis in Hematopoietic Stem Cells Exposed to Ionizing Radiation
The study examined the terminal maturation of megakaryocytes and platelet production in hematopoietic stem/progenitor cells exposed to ionizing radiation. [Radiat Res] Abstract

Evaluation of Volume and Total Nucleated Cell Count as Cord Blood Selection Parameters: A Receiver Operating Characteristic Curve Modeling Approach
The objective of the study was to evaluate the current standard practice of using volume and total nucleated cell count for the selection of cord blood units for cryopreservation and further transplantation. [Am J Clin Pathol] Abstract

Cultured Human Mast Cells Are Heterogeneous for Expression of the High-Affinity IgE Receptor FcεRI
Researchers determined the density of FcεRI on mast cells cultured from cord and peripheral blood and studied the kinetics of the response through FcεRI. [Int Arch Allergy Immunol] Abstract

Correlation Between Chemokines Released from Umbilical Cord Blood–Derived Mesenchymal Stem Cells and Engraftment of Hematopoietic Stem Cells in Nonobese Diabetic/Severe Combined Immunodeficient (Nod/Scid) Mice
The authors categorized umbilical cord blood (UCB)-derived mesenchymal stem cells (MSCs) as the least-effective MSCs or most-effective MSCs at enhancing the engraftment of hematopoietic stem cells, and compared the gene expression profiles of various cytokines and growth factors in the UCB-MSC populations. [Pediatr Hematol Oncol] Abstract

ViaCord Nabs Rights to TRT’s Platform for Extracting Stem Cells from Cord Tissue
ViaCord® negotiated exclusive U.S. rights to Tissue Regeneration Therapeutics’ (TRT) human umbilical cord perivascular cell technology for extracting mesenchymal stem cells from the tissue surrounding umbilical cord vessels. [Genetic Engineering & Biotechnology News] Press Release

Cord Blood America Growing Stem Cell Storage Business through Referrals
Cord Blood America, Inc. announced that since it launched a Referral Rewards Program on July 7, 2011, referral sales have risen from 8 to 21 percent of total sales. [Cord Blood America, Inc.] Press Release

Cryo-Save Group N.V. – Strong Third Quarter Results
Cryo-Save Group N.V. announced its trading update for the quarter ended 30 September 2011. [Cryo-Save Group N.V.] Press Release

Golden Meditech Chairman Increases Stake in Company
Golden Meditech Holdings Limited announced that the Group’s Chairman, Mr. KAM Yuen, and his family have purchased 53,828,000 shares of the Company from the open market on the disclosure date (October 27, 2011), at the average price of HK$0.85 per share via a representative holding company, as per disclosed to the Hong Kong Exchanges and Clearings Limited. [Golden Meditech Holdings Limited] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Lab Technologist – Tissue Culture (STEMCELL Technologies) 

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist – Cell Separation (STEMCELL Technologies)

Senior Laboratory Technician – Life Sciences (Matchtech)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.